Step-up and step-down treatments for optimal asthma control in children and adolescents

References

• Centers for Disease Control and Prevention: Most Recent Asthma Data. Updated 15 May 2018. Available from: https://www.cdc.gov/asthma/most_recent_data.htm. [last accessed 1 Aug 2018].
   Google Scholar
• Global Initiative for Asthma: GINA report, global strategy for asthma management and prevention. 2018. Available from: https://www.ginasthma.org [last accessed 25 April 2018].
   Google Scholar
• National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma: full report. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf [last accessed 27 Nov 2017].
   Google Scholar
• Hall C, Nici L, Sood S, ZuWallack R, Castro M. Nonpharmacologic therapy for severe persistent asthma. J Allergy Clin Immunol Pract 2017;5:928–935.
   PubMed Web of Science ®Google Scholar
• Klok T, Kaptein AA, Brand PLP. Improving adherence in paediatric respiratory disease. Breathe 2013;9:268–277.
   Google Scholar
• Michaud P-A, Suris JC, Viner R. The adolescent with a chronic condition: epidemiology, developmental issues and health care provision. Geneva, Switzerland: World Health Organization Press; 2007.
   Google Scholar
• Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database Syst Rev 2014;CD009471.
   PubMed Web of Science ®Google Scholar
• Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose–response effects on growth. Evid Based Child Health 2014;9:931–1046.
   PubMedGoogle Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064–1069.
   PubMed Web of Science ®Google Scholar
• Norjavaara E, Gerhardsson De Verdier M, Lindmark B. Reduced height in Swedish men with asthma at the age of conscription for military service. J Pediatr 2000;137:25–29.
   PubMed Web of Science ®Google Scholar
• Wardenier NRA, Klok T, de Groot EP, Brand PLP. Height growth in children with asthma treated with guideline-recommended dosages of fluticasone and electronically assessed adherence. Arch Dis Child 2016;101:637–639.
   PubMed Web of Science ®Google Scholar
• Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307–1317.
   PubMed Web of Science ®Google Scholar
• Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006;96:800–807.
   PubMed Web of Science ®Google Scholar
• Gillman SA, Anolik R, Schenkel E, Newman K. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 2002;41:333–340.
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64–77.
   PubMed Web of Science ®Google Scholar
• The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054–1063.
   PubMed Web of Science ®Google Scholar
• Jónasson G, Carlsen KH, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000;55:740–748.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen Y-Z, Ohlsson SV, Ullman A, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071–1076.
   PubMed Web of Science ®Google Scholar
• Price JF, Russell G, Hindmarsh PC, Weller P, Heaf DP, Williams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997;24:178–186.
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985–1997.
   PubMed Web of Science ®Google Scholar
• Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, Konig P, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998;132:472–477.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004;113:e87–e94.
   PubMed Web of Science ®Google Scholar
• Roux C, Kolta S, Desfougères J-L, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics 2003;111:e706–e713.
   PubMed Web of Science ®Google Scholar
• Bensch GW, Greos LS, Gawchik S, Kpamegan E, Newman KB. Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2011;107:323–329.
   PubMed Web of Science ®Google Scholar
• Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008;121:e1–14.
   PubMed Web of Science ®Google Scholar
• Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4–9 years old with mild persistent asthma. J Asthma 2011;48:848–859.
   PubMed Web of Science ®Google Scholar
• Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One 2015;10:e0133428.
   PubMed Web of Science ®Google Scholar
• Forero R, Bauman A, Young L, Booth M, Nutbeam D. Asthma, health behaviors, social adjustment, and psychosomatic symptoms in adolescence. J Asthma 1996;33:157–164.
   PubMed Web of Science ®Google Scholar
• Diette GB, Markson L, Skinner EA, Nguyen TTH, Algatt-Bergstrom P, Wu AW. Nocturnal asthma in children affects school attendance, school performance, and parents' work attendance. Arch Pedr Adolesc Med 2000;154:923–928.
   PubMed Web of Science ®Google Scholar
• Moonie S, Sterling DA, Figgs LW, Castro M. The relationship between school absence, academic performance, and asthma status. J Sch Health 2008;78:140–148.
   PubMed Web of Science ®Google Scholar
• Bruzzese JM, Evans D, Kattan M. School-based asthma programs. J Allergy Clin Immunol 2009;124:195–200.
   PubMed Web of Science ®Google Scholar
• Desai M, Oppenheimer JJ. Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep 2011;11:454–464.
   PubMed Web of Science ®Google Scholar
• Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, Szefler SJ, et al. Development and validation of the Composite Asthma Severity Index–an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012;129:694–701.
   PubMed Web of Science ®Google Scholar
• Lemanske RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975–985.
   PubMed Web of Science ®Google Scholar
• Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 2015;163:756–767.
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;CD002314.
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev 2013;CD009585.
   PubMed Web of Science ®Google Scholar
• Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94:60–70.
   PubMed Web of Science ®Google Scholar
• Chen X, Kang YB, Wang LQ, Li Y, Luo YW, Zhu Z, Chen R. Addition to inhaled corticosteroids of leukotriene receptor antagonists versus theophylline for symptomatic asthma: a meta-analysis. J Thorac Dis 2015;7:644–652.
   PubMed Web of Science ®Google Scholar
• Turner SW, Richardson K, Burden A, Thomas M, Murray C, Price D. Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study. NPJ Prim Care Respir Med 2015;25:15041.
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2015;CD007949.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012;CD006923.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013;CD006924.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013;CD006922.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012;CD007695.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). 2018. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm [last accessed 8 Mar 2018].
   Google Scholar
• Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, Avis M, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol 2016;138:441–450.e8 .
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, Engel M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J 2017;49:1601100.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Downie J, Nething K, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med 2014;108:1268–1276.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res 2015;16:20.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Murphy K, Harper T 3rd, Boner A, Laki I, Engel M, El Azzi G, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol 2017;140:1277–1287.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim: FDA expands approval of Spiriva^® Respimat^® (tiotropium bromide) inhalation spray for maintenance treatment of asthma in children. 2017. Available from: https://www.boehringer-ingelheim.us/press-release/fda-expands-approval-spiriva-respimat-tiotropium-bromide-inhalation-spray [last accessed 27 Nov 2017].
   Google Scholar
• Huang J, Chen Y, Long Z, Zhou X, Shu J. Clinical efficacy of tiotropium in children with asthma. Pak J Med Sci 2016;32:462–465.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodríguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2015;115:211–216.
   PubMed Web of Science ®Google Scholar
• Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, Szefler SJ, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2018;6:127–137.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Laki I, Bernstein JA, Schmidt O, El Azzi G, Moroni-Zentgraf P, et al. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J Allergy Clin Immunol Pract. 2018. doi: 10.1016/j.jaip.2018.04.032. (Epub ahead of print).
   Web of Science ®Google Scholar
• Genentech: FDA approves Genentech’s Xolair^® (omalizumab) for allergic asthma in children. 2016. Available from: http://www.gene.com/media/press-releases/14632/2016-07-07/fda-approves-genentechs-xolair-omalizuma [last accessed 5 Jan 2018].
   Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005–1015.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210–1216.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol 2015;15:267–271.
   PubMed Web of Science ®Google Scholar
• Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1–342.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodríguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139:28–35.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015;26:551–556.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline LLC. Highlights of prescribing information: Nucala. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526orig1s000lbl.pdf [last accessed 13 Jun 2018].
   Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Jackson DJ. Emerging issues in pediatric asthma: gaps in EPR-3 guidelines for infants and children. Curr Allergy Asthma Rep 2014;14:477
   PubMed Web of Science ®Google Scholar
• Akashi K, Mezawa H, Tabata Y, Atsuta J, Tokuda R, Kawada Y, Kitamura T, et al. Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: a randomized, controlled trial (OSCAR study). Allergol Int 2016;65:306–311.
   PubMed Web of Science ®Google Scholar
• Chiu K-C, Chou Y-L, Hsu J-Y, Lin M-S, Lin C-H, Chou P-C, Chou C-L, et al. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study. NPJ Prim Care Respir Med 2014;24:14010.
   PubMed Web of Science ®Google Scholar
• Harada S, Harada N, Itoigawa Y, Katsura Y, Kasuga F, Ishimori A, Makino F, et al. Evaluation of switching low-dose inhaled corticosteroid to pranlukast for step-down therapy in well-controlled patients with mild persistent asthma. J Asthma 2016;53:207–212.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Kraft M, Krishnan JA, Cloutier MM, Lazarus SC, Li JT, Santesso N, et al. Long-acting β2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012;172:1365–1375.
   PubMedGoogle Scholar
• Kew KM, Beggs S, Ahmad S. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. Cochrane Database Syst Rev 2015;CD011316.
   PubMed Web of Science ®Google Scholar
• Rank MA, Branda ME, McWilliams DB, Johnson SK, Samant SA, Podjasek JC, Park MA, et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol 2013;110:354–358. e352.
   PubMed Web of Science ®Google Scholar
• Bereznicki BJ, Beggs S, Duff C, Bereznicki L. Adherence to management guidelines for childhood asthma in Australia. Aust Fam Physician 2015;44:933–938.
   PubMed Web of Science ®Google Scholar
• Rank MA, Liesinger JT, Branda ME, Gionfriddo MR, Schatz M, Zeiger RS, Shah ND, et al. Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. J Allergy Clin Immunol 2016;137:1373–1379. e1373.
   PubMed Web of Science ®Google Scholar
• Price D, Chisholm A, Hillyer E, et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. J Aller Ther 2013;4:1.
   Google Scholar
• Roche N, Pribil C, Devillier P, Van Ganse E, Schück S, Doussaint J, Martin J, et al. Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. J Asthma 2016;53:76–85.
   PubMed Web of Science ®Google Scholar